European Journal of Inflammation

Scope & Guideline

Connecting researchers in the fight against inflammation.

Introduction

Immerse yourself in the scholarly insights of European Journal of Inflammation with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN1721-727x
PublisherSAGE PUBLICATIONS INC
Support Open AccessYes
CountryUnited States
TypeJournal
Convergefrom 2004 to 2024
AbbreviationEUR J INFLAMM / Eur. J. Inflamm.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address2455 TELLER RD, THOUSAND OAKS, CA 91320

Aims and Scopes

The European Journal of Inflammation focuses on advancing the understanding of inflammation and its multifaceted roles in various diseases. It encompasses a wide array of studies that explore both basic and clinical aspects of inflammation, emphasizing the importance of inflammatory pathways in health and disease.
  1. Mechanisms of Inflammation:
    The journal publishes research that elucidates the cellular and molecular mechanisms underlying inflammation, including studies on cytokines, chemokines, and immune cell interactions.
  2. Clinical Implications of Inflammation:
    Research focusing on the clinical consequences of inflammatory processes in diseases such as autoimmune disorders, infections, and cancer is a core area, providing insights that can influence treatment strategies.
  3. Biomarkers and Diagnostics:
    Papers often investigate potential biomarkers for inflammation-related diseases, enhancing diagnostic capabilities and prognostic assessments.
  4. Therapeutic Approaches:
    The journal highlights innovative therapeutic strategies targeting inflammatory pathways, including pharmacological interventions and novel treatments.
  5. Cross-disciplinary Studies:
    Research that integrates fields such as immunology, oncology, cardiology, and pulmonology, reflecting the interdisciplinary nature of inflammation research.
The European Journal of Inflammation is currently seeing an increase in publications addressing novel and relevant themes in inflammation research. These emerging scopes reflect the evolving landscape of medical science and current global health challenges.
  1. COVID-19 and Inflammation:
    With the ongoing impact of the COVID-19 pandemic, studies examining the inflammatory responses associated with the virus and its long-term effects are trending, highlighting the urgent need for understanding virus-induced inflammation.
  2. Inflammation and Metabolic Disorders:
    Research linking inflammation with metabolic conditions, such as diabetes and obesity, is gaining traction, indicating a growing recognition of the interplay between metabolic health and inflammatory processes.
  3. Immunotherapy and Inflammation:
    There is a rising interest in the role of inflammation in immunotherapy, particularly in cancer treatment, showcasing the relevance of inflammatory pathways in enhancing therapeutic efficacy.
  4. Inflammation in Neurological Disorders:
    Investigations into the role of inflammation in neurological conditions, including Alzheimer’s disease and multiple sclerosis, are emerging as a significant area of research, reflecting a broader interest in neuroinflammation.
  5. Microbiome and Inflammation:
    The relationship between the microbiome and inflammatory responses is increasingly highlighted, suggesting a complex interplay that could offer new therapeutic targets.

Declining or Waning

While the journal has consistently focused on inflammation, certain themes appear to be declining in prominence based on recent publications. This may reflect shifting research interests or advancements in understanding.
  1. Chronic Inflammatory Diseases:
    Research specifically focused on chronic inflammatory diseases such as rheumatoid arthritis and lupus has seen a decrease, possibly due to saturation in the field or a shift towards more acute inflammatory responses.
  2. Traditional Pharmacological Approaches:
    There is a noted reduction in studies solely focused on established pharmacological treatments for inflammation, indicating a transition towards exploring novel therapeutic avenues.
  3. Basic Science of Inflammation:
    Basic science studies that do not translate into clinical implications are becoming less frequent, suggesting a preference for research with direct clinical relevance.

Similar Journals

Central European Journal of Immunology

Advancing Immunological Frontiers Together
Publisher: TERMEDIA PUBLISHING HOUSE LTDISSN: 1426-3912Frequency: 4 issues/year

Central European Journal of Immunology is a premier publication dedicated to advancing the field of immunology and allergy research. Established in 1996 and published by TERMEDIA PUBLISHING HOUSE LTD, this open access journal has consistently provided a platform for innovative research and comprehensive reviews since its transition to open access in 2002. With an ISSN of 1426-3912 and E-ISSN of 1644-4124, it embraces a global readership while being rooted in Poland. The journal, with a notable Q3 ranking in both the categories of immunology and allergy in 2023, positions itself within the competitive landscape of scientific discourse, as reflected in its Scopus rankings. Designed for researchers, professionals, and students, the Central European Journal of Immunology not only disseminates significant findings but also fosters collaboration and innovation in the immunological sciences, making it a vital resource for those seeking to stay current in this rapidly evolving field.

JOURNAL OF EXPERIMENTAL MEDICINE

Exploring the Depths of Disease Mechanisms
Publisher: ROCKEFELLER UNIV PRESSISSN: 0022-1007Frequency: 12 issues/year

JOURNAL OF EXPERIMENTAL MEDICINE, published by Rockefeller University Press, is a renowned peer-reviewed journal dedicated to advancing the field of experimental medicine since its inception in 1896. With an impressive impact factor and categorized in the Q1 quartile for Immunology, Immunology and Allergy, and Miscellaneous Medicine, this journal stands at the forefront of medical research and innovation. It provides a prestigious platform for scholars and practitioners to disseminate groundbreaking findings that drive the understanding of disease mechanisms and therapeutic strategies. While the journal is not open access, it maintains high visibility and engagement within the scientific community, fostering collaboration among researchers, professionals, and students alike. The journal's consistent ranking in the top percentiles of Scopus illustrates its significant impact and commitment to excellence in medical research.

IN VIVO

Unveiling the complexities of life sciences for a healthier tomorrow.
Publisher: INT INST ANTICANCER RESEARCHISSN: 0258-851XFrequency: 6 issues/year

IN VIVO is a prestigious academic journal published by the International Institute of Anticancer Research, dedicated to advancing the fields of biochemistry, genetics, molecular biology, cancer research, and pharmacology. With its ISSN 0258-851X and E-ISSN 1791-7549, this journal has been a key contributor to innovative research since its inception in 1987, providing a crucial platform for the dissemination of significant findings in its scope. With an impressive impact reflected in its quartile rankings (Q2 in Biochemistry, Genetics and Molecular Biology and Medicine; Q3 in Cancer Research and Pharmacology), IN VIVO reaches a global audience comprising researchers, health professionals, and students. Although it operates on a subscription basis, the journal’s commitment to scientific excellence and rigorous peer review ensures that all published works maintain high quality and relevance. Notably positioned in Scopus ranks within the 36th to 59th percentiles across various categories, IN VIVO continues to be a vital resource for cutting-edge research and developments, solidifying its importance within the scientific community.

International Journal of Inflammation

Unleashing Knowledge in Immunology and Allergy
Publisher: HINDAWI LTDISSN: 2090-8040Frequency:

The International Journal of Inflammation, published by HINDAWI LTD, serves as a vital resource within the field of Immunology and Allergy. With an established Open Access policy since 2010, this journal provides unrestricted access to cutting-edge research, fostering collaboration and dissemination of knowledge among researchers, professionals, and students. The journal’s ISSN is 2090-8040 and E-ISSN 2042-0099. Situated in the United States with administrative offices in England, it has consistently contributed to the academic community, evidenced by its ranking in the Q3 category for 2023, reflecting its significant presence in the field. Covering a wide range of topics from the molecular basis of inflammation to clinical implications and treatment strategies, the journal engages with the latest developments and current debates. With a Scopus rank of 145 out of 233 in the category of Medicine, its percentile rank of 37th indicates its influence and relevance in contemporary research. As the journal continues to evolve from its convergence years spanning from 2012 to 2024, it remains committed to advancing knowledge and innovation in inflammation research.

Immuno

Empowering Discoveries in Immunology, Biochemistry, and Genetics
Publisher: MDPIISSN: Frequency: 4 issues/year

Welcome to Immuno, a pioneering open-access journal published by MDPI that serves as a key platform for the dissemination of innovative research in the fields of immunology, biochemistry, and genetics. Established in 2021, this journal has rapidly established itself within the academic community, currently ranking in the 53rd percentile in Medicine (miscellaneous) and 50th percentile in Biochemistry, Genetics, and Molecular Biology according to Scopus metrics. With a commitment to advancing our understanding of immune mechanisms and their applications in health and disease, Immuno is dedicated to publishing high-quality peer-reviewed articles that contribute valuable insights to both researchers and practitioners. Positioned in the heart of Switzerland, its global accessibility and diverse editorial board are a testament to its aim to promote knowledge exchange among scientists, practitioners, and students alike. Explore the latest discoveries and advancements in immunological research through Immuno, where your contributions help shape the future of this critical area of study.

FASEB JOURNAL

Illuminating the Pathways of Health and Disease
Publisher: WILEYISSN: 0892-6638Frequency: 12 issues/year

FASEB JOURNAL, published by Wiley, stands as a leading interdisciplinary platform in the realm of biological sciences, prominently featured in the United States. With an impressive 2023 impact factor placing it in the Q1 category across various fields including Biochemistry, Biotechnology, Genetics, Molecular Biology, and Medicine (miscellaneous), the journal is recognized for its substantial contribution to advancing knowledge and innovation. It serves as a vital resource for researchers, professionals, and students alike, providing high-quality, peer-reviewed articles that explore the molecular and cellular mechanisms underlying health and disease. The FASEB JOURNAL not only emphasizes accessible scientific communication but also fosters collaboration within these dynamic fields, making it an essential publication for anyone engaged in cutting-edge life sciences research. To explore more about the journal's offerings and access its vast repository of scholarly articles, visit their official page.

INFLAMMATION RESEARCH

Transforming theories into practical applications in health.
Publisher: SPRINGER BASEL AGISSN: 1023-3830Frequency: 12 issues/year

INFLAMMATION RESEARCH, published by SPRINGER BASEL AG, serves as a pivotal journal in the fields of Immunology and Pharmacology, with notable rankings of Q2 in Immunology and Q1 in Pharmacology as of 2023. With an ISSN of 1023-3830 and an E-ISSN of 1420-908X, this esteemed journal, located in Basel, Switzerland, has been at the forefront of advancing our understanding of inflammatory processes since its inception in 1995. Covering research trends and breakthroughs until 2024, it significantly contributes to both the theoretical frameworks and practical applications within its discipline, boasting a strong Scopus ranking of #40/313 in Pharmacology and #56/236 in Immunology, placing it in the top percentiles for its field. Although it does not offer Open Access options, the journal remains an invaluable resource for researchers, professionals, and students committed to unraveling the complexities of inflammation and its implications in health and disease.

INTERNATIONAL IMMUNOLOGY

Pioneering Research at the Intersection of Immunology and Medicine.
Publisher: OXFORD UNIV PRESSISSN: 0953-8178Frequency: 12 issues/year

INTERNATIONAL IMMUNOLOGY, published by OXFORD UNIV PRESS, stands out as a premier journal in the field of immunology, providing a vital platform for disseminating groundbreaking research and innovative developments within the discipline. With an impressive Q1 ranking in Immunology and Allergy, as well as in Medicine (miscellaneous), it consistently showcases high-impact studies that contribute to the advancement of immunological knowledge. The journal spans over three decades, from its inception in 1989 to its ongoing contributions as of 2024, thus solidifying its reputation in the scientific community. Researchers, professionals, and students will find valuable articles that delve into the complexities of immune responses, therapeutic interventions, and emerging immunological paradigms, ensuring INTERNATIONAL IMMUNOLOGY remains at the forefront of knowledge in the life sciences.

Immune Network

Bridging Disciplines for a Healthier Tomorrow
Publisher: KOREA ASSOC IMMUNOLOGISTSISSN: 1598-2629Frequency: 6 issues/year

Immune Network is a prestigious journal dedicated to disseminating high-quality research in the field of immunology, infectious diseases, and allergy, under the esteemed KOREA ASSOCIATION OF IMMUNOLOGISTS. Founded in 2016, this journal has quickly ascended to a top-tier publication, achieving Q1 rankings in 2023 in multiple relevant categories, including Immunology, Allergy, and Infectious Diseases. With a strong emphasis on innovation and interdisciplinary research, Immune Network appeals to a diverse audience of researchers, professionals, and students keen on advancing the understanding of immune responses and disease mechanisms. However, it is crucial to note that the journal operates under a subscription model without open-access provisions. Its impact factor further solidifies its reputation, reflecting the significant influence of the articles published. Located in South Korea, the journal serves as a global platform for sharing revolutionary insights and fostering collaborations within the immunology community.

JOURNAL OF IMMUNOLOGY

Advancing Immunological Frontiers
Publisher: AMER ASSOC IMMUNOLOGISTSISSN: 0022-1767Frequency: 24 issues/year

Welcome to the JOURNAL OF IMMUNOLOGY, a prestigious publication associated with the American Association of Immunologists and dedicated to advancing the field of immunology. With a rich history dating back to 1945, this journal is renowned for its high-impact research, evident in its notable 2023 Q1 rankings in both Immunology and Allergy, as well as its strong positions in Scopus rankings—Rank #68 in Immunology and Allergy and Rank #79 in Immunology and Microbiology. Although it operates on a subscription basis, its commitment to publishing cutting-edge studies ensures that it remains a vital resource for scientists, healthcare professionals, and students alike. As the journal continues to pave the way for innovative research and breakthroughs in immunological science, it facilitates a platform for dialogue and discovery among researchers and practitioners across the globe.